| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LPAR1 |
| Uniprot No | Q92633 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-364aa |
| 氨基酸序列 | MAAISTSIPVISQPQFTAMNEPQCFYNESIAFFYNRSGKHLATEWNTVSK LVMGLGITVCIFIMLANLLVMVAIYVNRRFHFPIYYLMANLAAADFFAGL AYFYLMFNTGPNTRRLTVSTWLLRQGLIDTSLTASVANLLAIAIERHITV FRMQLHTRMSNRRVVVVIVVIWTMAIVMGAIPSVGWNCICDIENCSNMAP LYSDSYLVFWAIFNLVTFVVMVVLYAHIFGYVRQRTMRMSRHSSGPRRNR DTMMSLLKTVVIVLGAFIICWTPGLVLLLLDVCCPQCDVLAYEKFFLLLA EFNSAMNPIIYSYRDKEMSATFRQILCCQRSENPTGPTEGSDRSASSLNH TILAGVHSNDHSVV |
| 预测分子量 | 68 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LPAR1重组蛋白的3篇参考文献示例：
1. **"Functional characterization of recombinant lysophosphatidic acid receptor 1 (LPAR1) in cancer cell migration"**
*作者：Fukushima N, et al.*
摘要：研究通过昆虫细胞系统表达重组LPAR1蛋白，证明其激活后通过Rho/ROCK信号通路促进乳腺癌细胞迁移，为靶向LPAR1的癌症治疗提供依据。
2. **"Structural insights into LPAR1 activation and G protein coupling"**
*作者：Chun J, et al.*
摘要：利用冷冻电镜解析重组LPAR1与G蛋白复合物的三维结构，揭示了溶血磷脂酸(LPA)结合后受体构象变化及下游信号转导机制。
3. **"LPAR1 recombinant protein-based screening identifies novel antifibrotic compounds"**
*作者：Tager AM, et al.*
摘要：通过重组LPAR1蛋白建立体外高通量筛选平台，发现小分子抑制剂可阻断TGF-β介导的肺成纤维细胞活化，为肺纤维化治疗提供新策略。
(注：以上文献信息为示例性概括，实际引用请核对具体文献内容。)
Lysophosphatidic acid receptor 1 (LPAR1), a member of the G protein-coupled receptor (GPCR) family, plays a critical role in mediating cellular responses to lysophosphatidic acid (LPA), a bioactive lipid involved in diverse physiological and pathological processes. LPAR1 activation triggers downstream signaling pathways, including Rho, MAPK, and PI3K, regulating cell proliferation, migration, and survival. Its involvement in fibrosis, cancer progression, inflammation, and neurological disorders has made it a target for therapeutic research.
Recombinant LPAR1 protein is engineered to study receptor-ligand interactions, signaling mechanisms, and drug discovery. Typically produced in mammalian expression systems (e.g., HEK293 cells) to ensure proper post-translational modifications and membrane protein folding, the recombinant protein often includes affinity tags (e.g., His-tag) for purification and detection. Purification involves techniques like immobilized metal affinity chromatography (IMAC) followed by size-exclusion chromatography to achieve high purity and stability.
Researchers use recombinant LPAR1 to screen agonists/antagonists, characterize binding kinetics, and model pathological pathways. For instance, LPAR1 inhibitors are explored for treating idiopathic pulmonary fibrosis and metastatic cancers. The protein’s structural analysis (e.g., cryo-EM studies) aids in understanding GPCR activation dynamics, guiding structure-based drug design. Challenges include maintaining receptor functionality in vitro due to its hydrophobic transmembrane domains and lipid-dependent activity. Nonetheless, recombinant LPAR1 remains a vital tool for deciphering LPA signaling and developing targeted therapies.
×
